JOHN REID PhD, MBA. (302)

Transcription

1 JOHN REID PhD, MBA (302) PROFILE Senior-level business development and licensing executive with a well-honed ability to translate scientific knowledge into business models and a significant record of success in delivering deals with pharmaceutical and biotechnology companies, institutes, and universities that foster productive collaborations, develop new technologies, and significantly strengthen the R&D pipeline. Broad cross-functional experience in external innovations, corporate strategy, and research operations. Highly accomplished at building and managing relations with US, European, and Asian pharmaceutical, biotechnology and academic entities. Hands-on experience leading multinational operational and scientific teams in deal negotiations, scientific evaluations, external partnerships, and R&D discovery projects. Extensive and broad deal experience (40 deals). Many accomplishments in science and business including scientific publications, research grants, drugs in clinical development, top-ranked education, professional appointments, and international recognition for landmark deals. Subject matter consultancy expertise with 24 publications. Experienced in all aspects of business development and external research management: managing competitive intelligence networks; developing strategic externalization plans; conducting outreach and sourcing of opportunities; managing scientific evaluation and due diligence; leading cross-functional deal teams; developing business cases with scientific analysis, risk assessment, sales forecasts and financial models; securing support for investments at all levels of management; negotiating complex transactions; structuring and leading post-deal alliance management. Excellent analytical, interpersonal and leadership skills able to see beyond the details and assess the broad competitive and strategic landscape. Strategic, motivated, creative, results-driven, people-centered leader with sound scientific and business judgment, able to motivate others, resolve issues and persistently overcome obstacles to deliver valuable business solutions. Strong project management, presentation and communication skills. Outstanding ability to bridge cultural and corporate differences in a collaborative team environment. Global professional network in the pharmaceutical, biotech, university, start-up and venture capital sectors. Dual US and Canadian citizenship. International experience with skills and expertise in: External Research Innovations o Business Development and Licensing o Scouting, Search and Evaluation o Alliance Management o Neuroscience, Oncology, Inflammation, Infection Corporate Strategy o Strategic Planning o Business Intelligence o Portfolio Management Research Operations

2 o o o Drug Discovery and Development Neuroscience, Alzheimer s Disease Molecular Biology ENTREPID BUSINESS DEVELOPMENT LLC Founder and Executive Director (2012-present) EXPERIENCE Develop unique consulting business that serves pharmaceutical companies engaged in partnering, licensing and acquiring drug candidates. Entrepid ( is focused on the key issues in Life Science Business Development clinical potential and business risk. Using a network of scientific experts, Entrepid provides independent scientific evaluation, risk assessment and due diligence of potential licensing candidates and subsequently translates the scientific knowledge into business terms that minimize risk and maximize value. ASTRAZENECA PHARMACEUTICALS US ( ) Director, Strategic Partnering and Business Development ( ) Strengthened and built the R&D pipeline using external alliances and licensing. Key member of a global team, responsible for early-stage Neuroscience Business Development in the US and Canada. Collaborated closely and effectively with business development leads in Oncology, Respiratory, Inflammation, and Infectious Disease Therapy Areas. Led cross-functional deal teams with responsibility for scientific, legal and intellectual property evaluations, business case development, contract negotiation and execution. Contributed to building the strongest external portfolio within AstraZeneca, with 43% of the pipeline and key technologies derived from external alliances. Delivered numerous research agreements, license agreements, CRADA, acquisitions, and strategic alliances many with innovative, risk-sharing, value-maximizing terms which resulted in a 48% reduction in the cost of delivering seven IND-ready candidate drugs. Negotiated major deals with U. Pennsylvania, PsychoGenics, Duke U., Columbia U., Mt. Sinai Medical, NIMH, Targacept, NPS Pharmaceuticals, U. Texas, Washington U., and the European Pain Research Network. Provided subject matter expertise and leadership for a global analysis of External Neuroscience Partnerships which was recognized for excellence by the senior executive team and led to a 55% increase in R&D funding for external alliances. Strengthened AstraZeneca s scientific reputation in Asia, as global lead for neuroscience research collaborations in Japan, responsible for review and selection of grant proposals from multiple Japanese universities. Director, Global Discovery Alliances and Business Development, Neuroscience ( ) Built the early stage pipeline and supported the Center of Excellence for Neuroscience Research in the US. through external research and licensing. Responsible for cross-therapy Area business collaborations in Oncology, Cardiovascular, Gastrointestinal and Inflammation. Managed early stage scouting and scientific evaluation, developed and presented business case proposals, negotiated contacts, secured support at all levels of management, and led alliance management. 2

3 Led team supporting preclinical CNS and Pain externalization strategy to deliver two new technologies, three candidate dugs and five research partnerships which significantly boosted the pipeline. Delivered new deals with Yale U., Argenta Discovery, Targacept Inc, Emory U and obtained maximum value from major alliances with Targacept, PsychoGenics, and NPS. Provided subject matter expertise as team member of the Global Alliance Management Task Force resulting in formation of a Center of Excellence and the highest scores in five years as Partner of Choice. Director, Global Alliance Management and Business Development ( ) Established and implemented high quality alliance management capabilities for Neuroscience external research across a portfolio of collaborations in the US, Europe and Asia. Led Alliance Management team activities with NPS Pharmaceuticals, Astex, Shanghai U., and Targacept, generating five new candidate drugs, and four new drug targets for the CNS and Gastrointestinal Therapy Areas. Took the lead in improving alliance management capabilities through the Partner of Choice Task Force and the Alliance Management Advisory Board, resulting in commitment to develop a companywide capability in alliance management. Developed an alliance network in major markets (Asia, Europe and North America) that positioned AZ Neuroscience as a partner of choice for partnering and licensing. Director, Strategic Planning and Knowledge Management ( ) Developed a cross-functional competitive intelligence network to provide senior management with actionable intelligence and develop strategic plans for external research. Spearheaded Competitive Intelligence analysis of the research pipeline that resulted in reprioritization of the portfolio and redeployment of resources to the most competitive projects. Played a lead role in developing the R&D Disease Area Strategy that led to formation of the AZ Center of Excellence in Neuroscience Founded and led the Frontiers in Psychiatry series of six high-profile workshops that delivered confidential discussions and recommendations on internal R&D projects from leading clinicians and key opinion leaders. Director and Head, Molecular Sciences Department ( ) Established and led a large Department at Astra Arcus US to utilize state-of-the-art technologies for CNS project generation and drug discovery. Provided departmental vision and strategic leadership to a team of Associate Directors, Scientists and Associate Scientists. Leadership role in the CNS Discovery Management and Project Teams supporting delivery of seven candidate drugs. Managed scientific and administrative operations for 40-person department with a $5M annual budget. Developed eight new drug discovery projects for Alzheimer s Disease, Parkinson s Disease, and Schizophrenia. Successfully led the Department through major change during merger with Zeneca, relocation from Rochester to Boston to Wilmington, and subsequent restructuring. OTHER PROFESSIONAL EXPERIENCE 2

4 ASTRA-ARCUS PHARMACEUTICALS (US), Section Head, Molecular Biology GLAXO INSTITUTE FOR MOLECULAR BIOLOGY (Switzerland), Scientist DNAX RESEARCH INSTITUTE (Palo Alto, CA), Postdoctoral Fellow GENENTECH INC (San Francisco, CA) Senior Research Associate EDUCATION M B A Healthcare Management / Finance, Le Bow College of Business, Drexel University C P D Business Development, The Wharton School, U. Penn, Philadelphia Ph D University of California, Berkeley, California B SC University of California, Davis, California EXTERNAL PROFESSIONAL APPOINTMENTS Business Advisor and QED Selection Team Member at the University Science Center-Philadelphia Entrepreneur at University of Pennsylvania- UPStart Program. Member - Board of Directors (AZ Rep): Association of University Technology Managers Leadership Council Member (AZ Rep): Society for Neuroscience Member (AZ Rep): Licensing Executive Society HONORS AND AWARDS Deal of Distinction 2010, Licensing Executive Society, co-recipient with U. Pennsylvania Deal of Distinction 2008, Licensing Executive Society, co-recipient with Targacept & GlaxoSmithKline Phi Kappa Phi Honor Society (Science) Beta Gamma Sigma Honor Society (Business) Strategic Alliance Management Professional Certification ADDITIONAL LEADERSHIP ACTIVITIES Vice President - Delaware State Squash Racquets Association Board of Directors and Head of Natural Land Management for the Stonewold Community Executive Board of Directors-Delaware Center for Contemporary Art Center for Creative Leadership Training and Development ADDITIONAL RELATED INFORMATION Deal Sheet (40 major deals, not including >100 MTAs, CDAs, grants and other small agreements) List of 24 peer reviewed publications Professional references from Pharmaceutical, Biotechnology and Academic Institutions INVITED PRESENTATIONS Perspectives on the Biotechnology and Commercialization Market, Global Technology-Modern Drug Discovery and Development Summit, Philadelphia 2012 Drug Discovery and Development Opportunities in Korea for Global Licensing and Partnership. Foreign Investment and Global BioMedical Forum, Seoul 2012 Global Drug Discovery and Development-Strategic Partnering and Business Development with AstraZeneca. Global Partnering Meeting, KOTRA Seoul

5 Symposium on Drug Discovery in Academia, Johns Hopkins University 2011 University/Industry Partnerships in a New Era of Drug Discovery, New York City BioForum 2011 The Changing Landscape of Drug Discovery Partnerships. AUTM Annual Meeting 2011 Are Academic Institutions Losing Their Way on Technology Transfer? LES Annual Meeting 2010 Innovative Deals with Universities, AUTM, Boston, 2008 Deal or No Deal: How to take the right risks to get the greatest rewards. LES Annual Meeting 2008 Negotiating for Alliance Success, LES Annual Meeting 2008, Orlando Securing and Managing the Transforming Deal, LES Annual Meeting 2007, San Francisco Global Strategies to Reinvent the R&D Business Model-Challenges in Partnerships and Alliances, R&D Executive Summit, San Francisco, 2007 BioPhama Opportunities in China-Drug Discovery Showcase, Shanghai, 2007 Frontiers of Biomedicine-Drug Research and Development, New York Academy of Science/ Chinese Academy of Science, Shanghai 2005 Chinese Academy of Science Conference on Neuroscience, Kunming, 2005 Neurodegenerative Disease Summit, New opportunities in CNS Drugs Princeton, 2005 CNS Discovery Showcase International Drug Discovery and Development Summit, Princeton, 2005 Licensing CNS Drugs, CNS Drug Discovery Congress, Philadelphia, 2004 Impact of Genetics on Psychiatric Drug Discovery, International Drug Discovery and Development Summit, Princeton,

6 5 John Reid